Medical workers of KinMed Diagnostics work to provide nucleic acid tests. [Photo/WeChat account: hefeigaoxinfabu]

KinMed Diagnostics (Hefei) has provided nucleic acid tests to more than 500,000 residents in the city of Wuhu, East China's Anhui province, as of 8 am on July 28 since the city launched citywide nucleic acid testing on July 24, according to the company.

The medical company responded quickly to help with local epidemic prevention and control efforts. It has sent a team of nearly 100 people as well as two mobile testing vehicles to the frontlines.

To increase efficiency and reduce infection risks, the company used self-developed COVID-19 testing monitoring systems to register residents’ information and deal with everyday testing information.

KinMed Diagnostics (Hefei) is experienced in dealing with urgent needs for COVID-19 testing, according to Shen Menglai, vice general manager of the company.

Last year, KinMed Diagnostics (Hefei) was awarded a provincial honor for its contributions to the fight against COVID-19. The company performed over 3 million COVID-19 tests in 15 cities in Anhui during the outbreak.

Established in 2007 in the Hefei National High-tech Industry Development Zone, KinMed Diagnostics (Hefei) is a national high-tech company engaged in medical examination and is a leading third-party medical laboratory in Anhui.

KinMed Diagnostics' mobile testing vehicle is used to help with COVID-19 testing efforts. [Photo/WeChat account: hefeigaoxinfabu]